Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-02-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-3118PMID 28246274
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Tivantinib (ARQ197) in hepatocellular carcinoma

  2015cited by this paper
• Abstract 1641: Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance

  2015cited by this paper
• Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

  2015cited by this paper
• Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1

  2015cited by this paper
• Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for ‘Off-Target' Effects Not Mediated by c-Met Inhibition

  2015cited by this paper
• Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma

  2015cited by this paper
• Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.

  2015cited by this paper
• The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

  2015cited by this paper
• Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

  2014cited by this paper
• Met as a therapeutic target in HCC: facts and hopes.

  2014cited by this paper
• MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma

  2014cited by this paper
• Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?

  2014cited by this paper
• Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

  2014cited by this paper
• Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

  2014cited by this paper
• The multiple facets of drug resistance: one history, different approaches

  2014cited by this paper
• A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

  2013cited by this paper
• A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

  2013cited by this paper
• Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

  2013cited by this paper
• High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

  2013cited by this paper
• Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

  2013cited by this paper
• Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma

  2013cited by this paper
• Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells

  2013cited by this paper
• MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

  2013cited by this paper
• Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

  2013influential reference
• NormaCurve: A SuperCurve-Based Method That Simultaneously Quantifies and Normalizes Reverse Phase Protein Array Data

  2012cited by this paper
• Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197

  2011cited by this paper
• Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

  2011cited by this paper
• ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

  2010cited by this paper
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• New cellular tools reveal complex epithelial–mesenchymal interactions in hepatocarcinogenesis

  2008cited by this paper
• Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

  2007cited by this paper
• Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

  2007cited by this paper
• Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

  2007cited by this paper
• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  2006cited by this paper
• Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo

  2005cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response.

  2000cited by this paper
• Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.

  1998cited by this paper

• MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation

  2025cites this paper
• Machine learning-powered discovery of a novel berberine derivative inducing SCD-dependent ferroptosis in osteosarcoma

  2025cites this paper
• Targeting MET Signalling Activated by CPNE3‐RACK1 Interaction Through VWFA Domain to Suppress Lung Cancer Progression

  2025influential citation
• Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma

  2025cites this paper
• The contribution of genetics and epigenetics to MAFLD susceptibility

  2024cites this paper
• British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults

  2024cites this paper
• Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence

  2024cites this paper
• The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis

  2023cites this paper
• Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

  2022cites this paper
• Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study

  2022cites this paper
• Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020).

  2021cites this paper
• Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling

  2021cites this paper
• Constitutive activity of GPR26 regulated by ubiquitin‐dependent degradation and its antitumor role

  2021cites this paper
• Signaling pathways in hepatocellular carcinoma.

  2021cites this paper
• 1 Title : Does timing matter in radiotherapy of hepatocellular carcinoma ?

  2021cites this paper
• Does timing matter in radiotherapy of hepatocellular carcinoma? An experimental study in mice

  2021cites this paper
• Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?

  2021cites this paper
• HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial–mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation

  2021cites this paper
• AICAR and Compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro.

  2021cites this paper
• c-Met as a potential therapeutic target in triple negative breast cancer

  2020cites this paper
• Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance

  2020cites this paper
• Deciphering MET‐dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics

  2020cites this paper
• Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

  2020cites this paper
• Time‐dependent changes in proliferation, DNA damage and clock gene expression in hepatocellular carcinoma and healthy liver of a transgenic mouse model

  2020cites this paper
• Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma

  2020cites this paper
• Advances in molecular classification and precision oncology in hepatocellular carcinoma.

  2020cites this paper
• Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

  2020cites this paper
• Phenotypic Response and Personalized Medicine in Liver Cancer and Transplantation: Approaches to Complex Systems

  2020cites this paper
• Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs.

  2019cites this paper
• Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

  2019cites this paper
• Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

  2019cites this paper
• MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.

  2019cites this paper
• Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.

  2019cites this paper
• ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance

  2019cites this paper
• Systemic Treatment for Advanced Hepatocellular Carcinoma

  2019cites this paper
• Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.

  2019cites this paper
• Molecular and histological correlations in liver cancer.

  2019cites this paper
• Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.

  2019cites this paper
• Hepatocellular Carcinoma: Translational Precision Medicine Approaches

  2019cites this paper
• Molecular-Targeted Therapies in Hepatocellular Carcinoma

  2019cites this paper
• Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma

  2019cites this paper
• Cabozantinib for the treatment of hepatocellular carcinoma

  2019cites this paper
• Polyploidy spectrum: a new marker in HCC classification

  2019cites this paper
• Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

  2019cites this paper
• A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

  2019cites this paper
• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

  2018cites this paper
• Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

  2018cites this paper
• Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics

  2018cites this paper
• LncRNA FLVCR1‐AS1 acts as miR‐513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma

  2018cites this paper
• Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas

  2018cites this paper
• The role of molecular enrichment on future therapies in hepatocellular carcinoma.

  2018cites this paper
• MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway

  2018cites this paper
• Molecular heterogeneity in hepatocellular carcinoma

  2018cites this paper
• Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR

  2018cites this paper
• MiR‐205 suppresses tumor growth, invasion, and epithelial‐mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma

  2018cites this paper
• Dynamics and predicted drug response of a gene network linking dedifferentiation with β-catenin dysfunction in hepatocellular carcinoma

  2018cites this paper
• Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma

  2018cites this paper
• Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma

  2017cites this paper
• Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy

  2017cites this paper
• Tivantinib for the treatment of hepatocellular carcinoma

  2017cites this paper
• Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.

  2017cites this paper
• The status of transarterial chemoembolization treatment in the era of precision oncology.

  2017cites this paper
• Cabozantinib in the treatment of hepatocellular carcinoma.

  2017cites this paper